Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting [Yahoo! Finance]
Foghorn Therapeutics Inc. (FHTX)
Company Research
Source: Yahoo! Finance
Conference call and webcast on April 9th at 5 p.m. ET / 2 p.m. PT CAMBRIDGE, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- March 26, 2024 -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced plans to host a conference call and webcast on April 9 th at 5 p.m. ET / 2 p.m. PT. Foghorn management will review key programs in its pipeline, including FHD-286 for acute myelogenous leukemia (AML), and new preclinical data being presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting for potential first-in-class medicines including FHD-909, a BRM (SMARCA2) selective inhibitor, and for the selective CBP and selective EP300 degrader programs. Conference Call Details Tuesday, April 9, at 5 p.m. ET / 2 p.m. PT Toll Free: 1-877-704-4453 International: 1-201-389-0920 Conference ID: 13745314 Webcast: Foghorn Even
Show less
Read more
Impact Snapshot
Event Time:
FHTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FHTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FHTX alerts
High impacting Foghorn Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
FHTX
News
- Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer [Yahoo! Finance]Yahoo! Finance
- Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial OfficerGlobeNewswire
- Foghorn Therapeutics Inc. (NASDAQ: FHTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.MarketBeat
- Foghorn Therapeutics Inc. (NASDAQ: FHTX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $13.00 price target on the stock.MarketBeat
- Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs [Yahoo! Finance]Yahoo! Finance
FHTX
Earnings
- 8/4/23 - Beat
FHTX
Sec Filings
- 4/17/24 - Form 4
- 4/17/24 - Form 3
- 4/16/24 - Form 8-K
- FHTX's page on the SEC website